Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for the company. This funding will enable SynAct to start a new phase IIa study in polymyalgia rheumatica, which will have a positive impact on our base case.
LÄS MER
